Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Benign Hematology

Journal Scan / Research · April 21, 2022

Safety and Efficacy of Mitapivat in Sickle Cell Disease

American Journal of Hematology


Additional Info

American Journal of Hematology
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study
Am. J. Hematol 2022 Apr 05;[EPub Ahead of Print], MJ van Dijk, MAE Rab, BA van Oirschot, J Bos, C Derichs, AW Rijneveld, MH Cnossen, E Nur, BJ Biemond, M Bartels, JJM Jans, WW van Solinge, REG Schutgens, R van Wijk, EJ van Beers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading